BioSpace News Archive

Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that Jason Aryeh, a long time biotech investor and board director, has been elected to the Cytovia Board of Directors, effective immediately

Hicuity Health, the nation’s leading provider of high-acuity telemedicine services, announced the expansion of its monitoring services to serve smart device providers and their end-users.

First Nation Group launches new division, First Nation Pharmaceuticals, offering generic pharmaceutical distribution and supply chain management

United Spinal Association has launched a membership drive in celebration of its 75 years of service to the spinal cord injury and disorder community, offering its members a chance to win a variety of prizes donated by companies committed to “Building an Inclusive World” for people with disabilities.

ZAP Surgical Systems, Inc. today announced the imminent installation of its advanced ZAP-X® Gyroscopic Radiosurgery® platform at the Swiss Neuro Radiosurgery Center (SNRC), an organization within the Swiss Clinical Neuroscience Institute (SCNSI) in Zurich, Switzerland.

Unique Commercial-Scale Capabilities for Highest-Quality Nanoemulsions of Oils in Water Enabled by PBI’s UST Platform, Addressing Multiple Billion Dollar Opportunities in Diverse Markets Worldwide

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to host its 2021 Virtual Investor Day on Thursday, June 3, 2021 beginning at 9:00am EDT

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced business highlights and financial results for the three months ended March 31, 2021.

Eledon Pharmaceuticals, Inc., (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today reported its first quarter 2021 operating and financial results.

Biofacturing leader Zymergen, today announced it will report financial results for the first quarter 2021 after market close on Monday, May 24th, 2021.